WO1991001740A1 - Process for producing pharmacosmetics - Google Patents

Process for producing pharmacosmetics Download PDF

Info

Publication number
WO1991001740A1
WO1991001740A1 PCT/HU1989/000039 HU8900039W WO9101740A1 WO 1991001740 A1 WO1991001740 A1 WO 1991001740A1 HU 8900039 W HU8900039 W HU 8900039W WO 9101740 A1 WO9101740 A1 WO 9101740A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ointment
pharmacosmetics
producing
toxin
Prior art date
Application number
PCT/HU1989/000039
Other languages
French (fr)
Inventor
Lajos Bodrogi
Péter PÓLUS
Lászlóné HETÉNYI
Original Assignee
Varánusz Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Varánusz Gm filed Critical Varánusz Gm
Priority to PCT/HU1989/000039 priority Critical patent/WO1991001740A1/en
Publication of WO1991001740A1 publication Critical patent/WO1991001740A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles

Definitions

  • the object of the invention is a process for producing pharmacosmetics comprising snake-venom.
  • the venom of Crotalus atrox is a complex active substance which has analgetic, hyperaemizating and spasmolysant activity at the same time and may be used for both therapeutic and veterinary purposes.
  • the compositions known from the literature do not dispose of such a complex and multiple activity.
  • composition produced by the process of the invention comprises thus the - preferably lyophilized - venom of Crotalus atrox as active substance, in a quantity of 0,0002 to 0,1 % as compared to the total amount of the composition, processed into ointment, aqueous suspension, emulsive composition, gel-formed composition, etc., with usual additives and/or auxiliaries.
  • the toxin Crotali atrocis is a light yellow, odourless powderj identity: dissolved in 1 mg of water and dropped on filter-paper with ninhydrin it discolours at a slight heat effect.
  • the composition is for external used in case of rheumatism, arthritis, arthrosis, ischias, lumbago, muscular aches occurring after sport achievements, and the like.
  • the production of the composition comprises - if processed for example as ointment - mixing methylsalicylate and camphoric acid at room temperature.
  • the lyophilized toxin Crotali atrocis is dissolved in distilled water, then mixed with methylsalicylate in a homogenizer of high speed of revolutions.
  • the aqueous toxin solution is added dropwise, the substance is then homogenized for 4 hours at least.
  • the suspension is added to a mass of ointment Unguenta composita (a mixture of equal proportion of polyoxetene 400 and polyoxetene 1540) and is homogenized for 6 to 8 hours at room temperature.
  • Unguenta composita a mixture of equal proportion of polyoxetene 400 and polyoxetene 1540
  • composition produced by the process of the invention is illustrated by the following non-limiting examples.
  • camphoric acid 3 0 g
  • toxin 1000 ⁇ g of toxin at the most, but preferably 50 ⁇ g of toxin are used.
  • the components are mixed according to the technology referred to above.
  • the ointment contains 5 to 20 % by mass of water and detergent may also be used.
  • the manufacturing technology is modified, i.e. the camphoric acid and methylsalicylate are mixed with 0,1-2,0 % of detergent, e.g. with Tween 20 or Ka-laurylsulfate.
  • conserving agents such as Sol. conservans may be added to the ointment, in a quantity of 0,1-0,5 % by mass.
  • aqueous suspension is produced.
  • Unguenta composita is replaced by ethyl alcohol in a concentration of 30-80 % by mass.
  • Emulsive composition is prepared by using sunflower oil instead of Unguenta composita and shaking up before use is stipulated in the instructions for use, or sunflower oil is used only in Unguenta composita instead of polyoxetene 1540.
  • Gel-formed composition is obtained if instead of polyoxetene 1540 3 % by mass of aqueous solution of hydroxymethylcellulose is used.
  • a stick of 3-4 cm of ointment is expressed on the skin surface and massaged by fine medico-massage on the aching spot (joint) for 5-10 minutes morning and evening, for six days.
  • the treatment is repeated 3-4 times.
  • the ointment cannot be used on skinless surfaces.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a method of producing pharmacosmetics comprising snake-venom. The method of the invention comprises processing the - preferably lyophilized - toxin Crotali atrocis as active substance, in a quantity of 0,0002 - 0,1 % as compared to the total amount of the composition, into ointment, aqueous suspension, emulsive composition, gel-formed composition and the like with usual additives and/or auxiliaries.

Description

PROCESS FOR PRODUCING PHARMACOSMETICS
Technical Field
The object of the invention is a process for producing pharmacosmetics comprising snake-venom.
Background Art
It is well known that the Soviet pharmaceutical industry produces and markets an ointment under the trade name Viprosal, the active ingredient of which is viper venom.
For veterinary purposes the venom of a snake belonging to Bungarus genus, of cobra (Kaja genus) and of Crotalus terrificus - differing from the species Crotalus atrox - has been used. These solutions are disclosed in patent specifications GB 1 446 234, US 4 027 012, 4 126 676 and 4 232 308.
Disclosure of the Invention
It has been found that the venom of Crotalus atrox is a complex active substance which has analgetic, hyperaemizating and spasmolysant activity at the same time and may be used for both therapeutic and veterinary purposes. The compositions known from the literature do not dispose of such a complex and multiple activity.
The composition produced by the process of the invention comprises thus the - preferably lyophilized - venom of Crotalus atrox as active substance, in a quantity of 0,0002 to 0,1 % as compared to the total amount of the composition, processed into ointment, aqueous suspension, emulsive composition, gel-formed composition, etc., with usual additives and/or auxiliaries.
The toxin Crotali atrocis is a light yellow, odourless powderj identity: dissolved in 1 mg of water and dropped on filter-paper with ninhydrin it discolours at a slight heat effect.
Determination of contents: nitrogen content 11,5 % at least according to Ph.Hg.VII (Hungarian Pharmacopoeia).
The composition is for external used in case of rheumatism, arthritis, arthrosis, ischias, lumbago, muscular aches occurring after sport achievements, and the like.
The production of the composition comprises - if processed for example as ointment - mixing methylsalicylate and camphoric acid at room temperature. The lyophilized toxin Crotali atrocis is dissolved in distilled water, then mixed with methylsalicylate in a homogenizer of high speed of revolutions. The aqueous toxin solution is added dropwise, the substance is then homogenized for 4 hours at least. The suspension is added to a mass of ointment Unguenta composita (a mixture of equal proportion of polyoxetene 400 and polyoxetene 1540) and is homogenized for 6 to 8 hours at room temperature. The obtained composition may be stored in dry, cool place for 5 years without decomposition.
Best Mode of Carrying out the Invention
The composition produced by the process of the invention is illustrated by the following non-limiting examples.
Example 1 (ointment)
The following components are mixed according to the technology described above:
Toxin Crotali atrocis sice. 0,001 g
methylsalicylate 6,0 g
camphoric acid 3,0 g
Unguenta composita ad 100,0 g
Example 2 (ointment)
In case of tubes of 50 g 10μg of toxin at the least,
1000 μg of toxin at the most, but preferably 50μg of toxin are used.
The components are mixed according to the technology referred to above.
In addition to the active substance, the ointment contains 5 to 20 % by mass of water and detergent may also be used.
In this case the manufacturing technology is modified, i.e. the camphoric acid and methylsalicylate are mixed with 0,1-2,0 % of detergent, e.g. with Tween 20 or Ka-laurylsulfate.
As additive, conserving agents, such as Sol. conservans may be added to the ointment, in a quantity of 0,1-0,5 % by mass.
Example 3
Instead of ointment, aqueous suspension is produced. In the formula of Example 1, Unguenta composita is replaced by ethyl alcohol in a concentration of 30-80 % by mass.
Example 4
Emulsive composition is prepared by using sunflower oil instead of Unguenta composita and shaking up before use is stipulated in the instructions for use, or sunflower oil is used only in Unguenta composita instead of polyoxetene 1540.
Example 5
Gel-formed composition is obtained if instead of polyoxetene 1540 3 % by mass of aqueous solution of hydroxymethylcellulose is used.
During the application for example a stick of 3-4 cm of ointment is expressed on the skin surface and massaged by fine medico-massage on the aching spot (joint) for 5-10 minutes morning and evening, for six days.
At one week intervals the treatment is repeated 3-4 times.
The ointment cannot be used on skinless surfaces.

Claims

C L A I M :
Process for producing pharmacosmetics comprising snake-venom, c h a r a c t e r i z e d i n that the - preferably lyophilized - toxin Crotali atrocis is processed as active substance, in a quantity of 0,0002 - 0,1 as compared to the total amount of the composition, into ointment, aqueous suspension, emulsive composition, gel-formed composition and the like with usual additives and/or auxiliaries.
PCT/HU1989/000039 1989-08-05 1989-08-05 Process for producing pharmacosmetics WO1991001740A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/HU1989/000039 WO1991001740A1 (en) 1989-08-05 1989-08-05 Process for producing pharmacosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU1989/000039 WO1991001740A1 (en) 1989-08-05 1989-08-05 Process for producing pharmacosmetics

Publications (1)

Publication Number Publication Date
WO1991001740A1 true WO1991001740A1 (en) 1991-02-21

Family

ID=10980844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1989/000039 WO1991001740A1 (en) 1989-08-05 1989-08-05 Process for producing pharmacosmetics

Country Status (1)

Country Link
WO (1) WO1991001740A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085391A1 (en) * 2001-04-24 2002-10-31 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
US6555109B1 (en) 1998-01-20 2003-04-29 S.I.S. Shulov Institute For Science Ltd. Analgesic from snake venom
EP1765851A2 (en) * 2004-05-06 2007-03-28 Laboratório Biosintética Ltda. Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
US7208150B1 (en) 1999-07-14 2007-04-24 S.I.S. Shulov Institute For Science Ltd. Analgesic from snake venom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639796A1 (en) * 1985-11-22 1987-07-09 Oncogen GROWTH-PREVENTING SNAKE POISIDE PEPTIDE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639796A1 (en) * 1985-11-22 1987-07-09 Oncogen GROWTH-PREVENTING SNAKE POISIDE PEPTIDE

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555109B1 (en) 1998-01-20 2003-04-29 S.I.S. Shulov Institute For Science Ltd. Analgesic from snake venom
US7208150B1 (en) 1999-07-14 2007-04-24 S.I.S. Shulov Institute For Science Ltd. Analgesic from snake venom
WO2002085391A1 (en) * 2001-04-24 2002-10-31 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
EP1765851A2 (en) * 2004-05-06 2007-03-28 Laboratório Biosintética Ltda. Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
EP1765851A4 (en) * 2004-05-06 2008-05-28 Laboratorios Biosintetica Ltda Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
US9109041B2 (en) 2004-05-06 2015-08-18 Yara Cury Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification

Similar Documents

Publication Publication Date Title
EP0098743B1 (en) Phenyl alpha-acyloxyacetamide derivates and their therapeutic use
DE69704426T2 (en) METHOD FOR PRODUCING MEDICAL CHEWING GUM WITH A GOOD TASTE, INCLUDING AN INCLUDING COMPOUND
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
FI890508A (en) Process for the preparation of pharmaceutically active 3-indolepyruvic acid derivatives
PH23248A (en) Process for the preparation of quinolone-carboxylic acid
RU93004907A (en) Hydroxamic Acid Derivatives and N-Hydroxyurea. METHOD FOR PRODUCING THE PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
NO179995C (en) Process for the preparation of low-toxicity drug-lipid systems containing polyene antibiotics
RU95111308A (en) Derivatives of 2-amino-4-phenyl-4-oxobutyric acid, methods of synthesis, pharmaceutical composition
US4735945A (en) Method for inhibiting bone resorption and collagenase release
DE69705414T2 (en) PURE, BIOLOGICALLY ACTIVE COLISTIN, ITS INGREDIENTS AND A COLISTIN PREPARATION FOR THE TREATMENT OF INFLAMMATORY RESPIRATION
DE69825733T2 (en) SPECIFIC INHIBITORS OF PANCREATIC LIPASE AND ITS APPLICATIONS
WO1991001740A1 (en) Process for producing pharmacosmetics
ATE3552T1 (en) PROCESS FOR THE PREPARATION OF PHOSPHONO-HYDROXY-ACETIC ACID AND SALTS THEREOF AND AUTIVIRALS CONTAINING THEM.
US6696419B1 (en) Boron compounds and complexes as anti-inflammatory agents
DK527186D0 (en) SOURCE CHODILATING PHARMACEUTICAL PREPARATION
AU732706B2 (en) Lipid-based immune modulator composition
Demirci et al. In vivo inhibition of inducible nitric oxide and evaluation of the brain tissue damage induced by Toxocara canis larvae in experimentally infected mice
RU2091065C1 (en) Ointment for psoriasis treatment
FR2384791A1 (en) NEW EVERNINOMICINE DERIVATIVES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAID DERIVATIVES
US6538155B1 (en) Method for preparing an EDTA-Tris composition, a composition containing EDTA-Tris and uses therefor
IT8024165A0 (en) ESTERS OF DIALOGENOVINILCICLOPROPANCARBOXYLIC ACIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE TO FIGHT HARMFUL ORGANISMS AND ALSO ALPHA-HALOGENETHYL-3-PHENOXYBENZYL ALCOHOL.
HU913009D0 (en) Method for producing inhibitors of calcium ingestion
JPS6434915A (en) Drug preparation for skin
EP1233772A1 (en) Boron compounds and complexes as anti-inflammatory agents
TNSN94110A1 (en) PROCESS FOR THE PREPARATION OF ORAL COMPOSITIONS CONTAINING QUINOLONES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE